Testosterone therapy improves sexual, urinary function in men

Men with hypogonadism treated long-term with testosterone therapy experience improvements in sexual and urinary function compared with men who are not treated, according to findings published in The Journal of Urology.

Abdulmaged M. Traish, PhD, of the department of biochemistry and department of urology at Boston University School of Medicine, and colleagues evaluated data on men with total testosterone levels of 12.1 nmol/L or less and symptoms of hypogonadism assigned to parenteral testosterone undecanoate 1,000 mg for 12 weeks (n = 360; mean age, 57.4 years) or no testosterone (n = 296; mean age, 64.8 years) for up to 10 years to determine the effect of long-term testosterone therapy on urinary and sexual functions and quality of life. Follow-up was a mean of 6.5 years.

Total testosterone levels were restored to the physiological range (500 ng/dL) in the treated group during the first year and the levels remained stable through follow-up; however, mean testosterone levels remained less than 300 ng/dL in the untreated group.

The untreated group experienced increases in the international prostate symptom score during follow-up compared with decreases in the treated group. At baseline, 50% of the treated group reported mild symptoms and 50% reported moderate symptoms, and 91.5% of the untreated group reported mild symptoms and 8.5% reported moderate symptoms. At the last visit, all the treated group had mild symptoms, and 61% of the untreated group reported mild symptoms and 39% reported moderate symptoms.

Post-voiding bladder volume and score on the Aging Males’ Symptoms scale decreased in the treated group but increased in the untreated group.

Among the treated group, 17.1% had no erectile dysfunction, 30.5% had mild erectile dysfunction, 20.7% mild to moderate, 25.6% moderate and 6.1% severe. At the last visit, the proportion of treated participants without erectile dysfunction increased to 74.4%, 17.1% had mild, 7.3% had mild to moderate and 1.2% had moderate. Among the untreated group, 1.2% had no erectile dysfunction, 31.7% had mild, 52.4% had mild to moderate and 14.6% had moderate. The severity of erectile dysfunction increased in the untreated group through follow-up to 51.2% having moderate and 48.8% having severe.

Prostate volume remained stable in the untreated group but increased from 31.4 mL to 33.2 mL in the treated group.

Article Source: https://www.healio.com/endocrinology/hormone-therapy/news/in-the-journals/%7B0c2f828d-0812-42fa-8f66-181eb9a8ee0f%7D/testosterone-therapy-improves-sexual-urinary-function-in-men

“The Greatest Health of Your Life”℠

Boston Testosterone Partners
National Testosterone Restoration for Men
Wellness & Preventative Medicine

http://www.BostonTestosterone.com

http://www.BTPWellness.com

http://www.facebook.com/CoreNewEngland
855-617-MEDS (6337)

©2017 All Rights Reserved.